内皮祖细胞与贝伐单抗治疗的非鳞状非小细胞肺癌治疗反应之间的关联
Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab.
作者信息
Sudo Kazuhisa, Sato Kazuhiro, Sakamoto Sho, Hasegawa Yukiyasu, Asano Mariko, Okuda Yuji, Takeda Masahide, Sano Masaaki, Watanabe Hiroyuki, Shioya Takanobu, Ito Hiroshi
机构信息
Department of Cardiovascular and Respiratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.
Department of Cardiovascular and Respiratory Medicine, Akita University Graduate School of Medicine, Akita, Japan
出版信息
Anticancer Res. 2017 Oct;37(10):5565-5571. doi: 10.21873/anticanres.11989.
BACKGROUND/AIM: To investigate the association between the number of circulating endothelial progenitor cells (EPCs) in non-squamous non-small cell lung cancer (NSCLC) and disease outcome, in combination chemotherapy with and without bevacizumab.
MATERIALS AND METHODS
We retrospectively identified 25 non-squamous NSCLC cases, and divided them into high-EPC and low-EPC groups. Within each group, we compared disease outcomes, with or without the administration of bevacizumab.
RESULTS
In the high-EPC group, chemotherapy with bevacizumab produced a significantly higher tumor reduction rate and objective response rate, with significantly longer progression-free survival, compared to chemotherapy without bevacizumab (p<0.001, p=0.010, and p<0.001, respectively). However, in the low-EPC group, there were no significant differences in disease outcomes in groups with versus those without bevacizumab.
CONCLUSION
The number of EPCs may be a useful biomarker to guide decision-making in the use of bevacizumab in non-squamous NSCLC.
背景/目的：研究非鳞状非小细胞肺癌（NSCLC）中循环内皮祖细胞（EPC）数量与疾病转归之间的关联，以及在联合化疗中使用和不使用贝伐单抗的情况。
材料与方法
我们回顾性地确定了25例非鳞状NSCLC病例，并将其分为高EPC组和低EPC组。在每组中，我们比较了使用或不使用贝伐单抗时的疾病转归。
结果
在高EPC组中，与不使用贝伐单抗的化疗相比，使用贝伐单抗的化疗产生了显著更高的肿瘤缩小率和客观缓解率，无进展生存期显著更长（分别为p<0.001、p=0.010和p<0.001）。然而，在低EPC组中，使用和不使用贝伐单抗的组在疾病转归方面没有显著差异。
结论
EPC数量可能是指导非鳞状NSCLC中使用贝伐单抗决策的有用生物标志物。
Zotero 插件